Skip to content

Effect and mechanism of Wei'erkang on chronic atrophic gastritis with dysplasia

Effect and mechanism of Wei'erkang on chronic atrophic gastritis with dysplasia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023453
Enrollment
Unknown
Registered
2019-05-28
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic atrophic gastritis with dysplasia

Interventions

A:Weierkang
B:Weierkang and Folic acid

Sponsors

Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Referring to consensus on chronic gastritis in China(Shanghai, 2017), the patients were diagnosed as CAG , aged 20-70 years. 1. Gastroscopic examination or NBI combined with magnifying gastroscopy was performed within 2 months before enrollment, and the gastric mucosa was found to be granular, mucosal blood vessels were exposed, gray color was dark, and wrinkles were fine; 2. Biopsy tissue pathology showed mucosal inflammation, divided into three levels. Mild: inflammatory cell infiltration at the bottom of the pit; moderate: inflammatory cells infiltrated deep into the lamina propria; severe: inflammatory cells infiltrated deep into the mucosal muscle layer. Atrophic gastritis manifests itself, intrinsic gland atrophy: less than 1/3 is mild; 1/3 to 2/3 is moderate; reduction is >2/3 is severe. At the same time, the degree of intestinal metaplasia and dysplasia were observed.

Exclusion criteria

Exclusion criteria: 1. Combined with malignant tumor,espencially esophageal cancer and gastric cancer; ulcer, barretts esophagus or other upper GI diseases; 2. Acid inhibitors (H2 antagonists or proton pump inhibitors) promote power medicine (mosapride or domperidone, etc.) or gastric mucosa protectant for pury (teprenone, sucralfate, gefarnate, glutamine, rebamipide, bismuth, etc.) were taken two weeks before this trial; 3. Serious comorbidities of heart, lung, liver, kidney or blood system; 4. Female patients preparing for a baby, pregnant or lactating; 5. Dropping out of this trials before the end of treatment, or can't cooperate with researchers.

Design outcomes

Primary

MeasureTime frame
Total effective rate;The effective rate;The reverse rate;

Countries

China

Contacts

Public ContactChen Shujie

Department of Gastroenterology, Sir Run Run Shaw Hospital

4094108@qq.com+86 13867489890

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026